Crain’s Detroit Business Profiles ALS Trial

"I know what a placebo effect is. I'm not crazy. This isn't a placebo effect," Ted Harada told one of his doctors last year, practically yelling it at him in a burst of enthusiasm.

Harada, 40, a former manager at FedEx Corp., was one of 15 ALS patients who were part of a recently completed U.S. Food and Drug Administration Phase 1 trial at Emory University in Atlanta -- a trial designed and run in part by researchers at the University of Michigan to inject stem cells into the spine of patients with amyotrophic lateral sclerosis.

Full article - ALS patient: 'This isn't a placebo effect' (PDF)

Stem cell research nears next phase; trials may come to Ann Arbor

Approval by the U.S. Food and Drug Administration is expected any day for researchers and physicians at the University of Michigan to begin a second round of Phase 1 stem cell trials on patients with amyotrophic lateral sclerosis, commonly known as Lou Gehrig's disease.

ALS is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement. It usually leads to death within three to five years. Currently, there is no cure.

Full article - Advancing on ALS (PDF)


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift